Patient access to orphan drugs in France | Orphanet Journal of Rare Diseases | Full Text
L/6589/Add.2 Addendum couvert du document L/6589/Add.1. La traduction non officielle de cette en el documents L/6589/Add.l. La t
Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France | PLOS ONE
Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System | Health Affairs
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) • The Journal of Prevention of Alzheimer's Disease
Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program - ScienceDirect
Patient access to orphan drugs in France | Orphanet Journal of Rare Diseases | Full Text
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France | PLOS ONE
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France | PLOS ONE
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France - Erin Johansson, Anders Gustavsson, Carolin Miltenburger, Korinna Karampampa, Lucien Rumbach, Karin Rérat, Celine Thonnelier, 2012
La base de données médicaments Thériaque - CNHIM
Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France | PLOS ONE
Vaccines | Free Full-Text | Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure | SpringerLink
Association des POIC - La base AMELI a enfin été mise à jour concernant la retrocession de la Trimebutine injectable. Aucune pharmacie centrale ne peut, désormais, refuser de la délivrer (sur prescription
Supplementary materials Methods Calculation of costs and HCRU A cost of €24.13, which included official tariffs and surcharges
Nouvelle indemnisation transparente pour les médicaments soumis à ordonnance | Communauté d'achat HSK SA
PowerPoint 簡報
utilisation des médicaments dans les maisons de soins - KCE
La base de données médicaments Thériaque - CNHIM
Full article: A comparative public health and budget impact analysis of pneumococcal vaccines: The French case
Vaccines | Free Full-Text | Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program - ScienceDirect
